Breaking News

Tweet TWEET

NuVasive(R) Announces Conference Call and Webcast of Second Quarter 2013 Results

NuVasive(R) Announces Conference Call and Webcast of Second Quarter 2013 Results 
SAN DIEGO, CA -- (Marketwired) -- 07/16/13 --  NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
minimally disruptive surgical products and procedures for the spine,
announced details today relating to its second quarter 2013 earnings
announcement, which will take place on Tuesday, July 30, 2013, after
the close of the market.  
NuVasive will hold a conference call on Tuesday, July 30, 2013, at
5:30 p.m. ET / 2:30 p.m. PT to discuss the results. The dial-in
numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470
for international callers. A live webcast of the conference call will
be available online from the investor relations page of the Company's
corporate website at www.nuvasive.com.  
After the live webcast, the call will remain available on NuVasive's
website, www.nuvasive.com through August 29, 2013. In addition, a
telephone replay of the call will be available until August 13, 2013.
The replay dial-in numbers are 1-877-870-5176 for domestic callers
and 1-858-384-5517 for international callers. Please use pin number:
417030. 
About NuVasive
 NuVasive is an innovative global medical device
company that is changing spine surgery with minimally disruptive
surgical products and procedurally integrated solutions for the
spine. The Company is the 4th largest player in the $8.2 billion
global spine market. 
NuVasive offers a comprehensive spine portfolio of more than 80
unique products developed to improve spine surgery and patient
outcomes. The Company's principal procedural solution is its Maximum
Access Surgery, or MAS(R) platform for lateral spine fusion. MAS
provides safe, reproducible, and clinically proven outcomes, and is a
highly differentiated solution with fully integrated neuromonitoring,
customizable exposure, and a broad offering of application-specific
implants and fixation devices designed to address a variety of
pathologies.  
Having pioneered the lateral approach to spine fusion, NuVasive
continues to be at the forefront of the spine industry's shift toward
less invasive solutions. The Company places a large focus on clinical
research and support of the Society of Lateral Access Surgery, or
SOLAS(R), to expand the body of clinical evidence in support of
NuVasive's minimally disruptive solutions and to drive adoption of
its techniques. The Company's dedication to innovation continues to
spawn game changing technology such as the PCM(R) motion preserving
disc for the cervical spine, XLIF(R) Corpectomy for tumor and trauma,
and Armada(R), which treats adult degenerative scoliosis in a less
invasive fashion. The Company has also developed procedural solutions
that completely redefine and improve upon traditional procedures like
TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are
increasingly being adopted internationally, as the Company lays the
groundwork to continue growing as a global business and to offer
industry-leading, Absolutely Responsive customer service to surgeons
world-wide. NuVasive is focused on becoming a $1 Billion
Start-up(TM); taking market share by maintaining a commitment to
Superior Clinical Outcomes, Speed of Innovation(R), and Absolute
Responsiveness(R).  
NuVasive cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical results
or those expressed or implied by such forward-looking statements. The
potential risks and uncertainties are described in NuVasive's press
releases and periodic filings with the Securities and Exchange
Commission. NuVasive's public filings with the Securities and
Exchange Commission are available at www.sec.gov. NuVasive assumes no
obligation to update any forward-looking statement to reflect events
or circumstances arising after the date on which it was made. 
Investor Contact:
Tina Jacobsen
NuVasive, Inc.
858-320-5215
investorrelations@nuvasive.com 
Media Contact: 
Nicole Collins
NuVasive, Inc.
858-909-1907
media@nuvasive.com 
 
 
Press spacebar to pause and continue. Press esc to stop.